Downregulation of miR‐146a, cyclooxygenase‐2 and advanced glycation end‐products in simvastatin‐treated older patients with hyperlipidemia
Downregulation of miR‐146a, cyclooxygenase‐2 and advanced glycation end‐products in simvastatin‐treated older patients with hyperlipidemia
复制标题
DOI：
10.1111/ggi.12472
复制
发表时间：
2016-03
影响因子：
3.3
通讯作者：
Z. Yang;Ya Zhen Wang;B. Jia;G. Mao;Yuandong Lv;Guo Fu Wang;Hong Yu
中科院分区：
文献类型：
--
作者：
Z. Yang;Ya Zhen Wang;B. Jia;G. Mao;Yuandong Lv;Guo Fu Wang;Hong Yu
高脂血症是血液中脂质/脂蛋白水平异常升高的疾病，被认为是心脑血管疾病的重要危险因素。人们发现他汀类药物可以通过降低低密度脂蛋白胆固醇和调节免疫反应来预防血管疾病。在此，我们旨在研究老年高脂血症患者接受辛伐他汀治疗后免疫相关microRNA和基因的表达变化。
Hyperlipidemia is a disease with abnormally elevated levels of lipids/lipoproteins in the blood, and it is regarded as an important risk factor for cardiovascular and cerebrovascular diseases. Statins have been found to prevent vascular diseases by reducing low‐density lipoprotein cholesterol and regulation of immune responses. Here, we aim to study the expression change of immune‐related microRNA and genes in older patients with hyperlipidemia after treatment with simvastatin.